Can you take Enzalutamide with Nerandomilast?
1 drug interaction and 9 additional warnings found for the following 2 drugs:
- enzalutamide
- nerandomilast
Drug interactions
Major drug interactions
Major:
enzalutamide nerandomilast
Applies to: enzalutamide and nerandomilast
Enzalutamide can significantly reduce the blood levels of nerandomilast, which may make the medication less effective in treating your condition.
Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact.
It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food/lifestyle interactions
Major food/lifestyle interactions
Major:
nerandomilast Food/Lifestyle
Applies to: nerandomilast
Nerandomilast should not be taken with grapefruit juice, as it may significantly increase the levels of medication in the blood.
This can increase the risk of side effects including:
- diarrhea
- depression
- decreased appetite
- weight loss
Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Disease interactions
8 potential interactions Applies to: 7 conditions, including Seizures, Head Injury, Liver Disease, Brain Tumor, and Renal Dysfunction.
Brain Tumor
Moderate:
enzalutamide
Enzalutamide has a moderate potential interaction with Brain Tumor.
Seizures occurred in 0.5% of patients receiving enzalutamide in clinical trials. Patients with predisposing factors for seizures were generally excluded. Caution is advised if using in patients with possible predisposing factors such as history of seizures, history of trauma or head injury, cerebrovascular accident or transient ischemic attack, Alzheimer's disease, meningioma or brain tumor or infection, and any unexplained loss of consciousness in the past 12 months. Enzalutamide should be discontinued permanently in any patient who develops a seizure during treatment.
CNS Infection
Moderate:
enzalutamide
Enzalutamide has a moderate potential interaction with CNS Infection.
Seizures occurred in 0.5% of patients receiving enzalutamide in clinical trials. Patients with predisposing factors for seizures were generally excluded. Caution is advised if using in patients with possible predisposing factors such as history of seizures, history of trauma or head injury, cerebrovascular accident or transient ischemic attack, Alzheimer's disease, meningioma or brain tumor or infection, and any unexplained loss of consciousness in the past 12 months. Enzalutamide should be discontinued permanently in any patient who develops a seizure during treatment.
Head Injury
Moderate:
enzalutamide
Enzalutamide has a moderate potential interaction with Head Injury.
Seizures occurred in 0.5% of patients receiving enzalutamide in clinical trials. Patients with predisposing factors for seizures were generally excluded. Caution is advised if using in patients with possible predisposing factors such as history of seizures, history of trauma or head injury, cerebrovascular accident or transient ischemic attack, Alzheimer's disease, meningioma or brain tumor or infection, and any unexplained loss of consciousness in the past 12 months. Enzalutamide should be discontinued permanently in any patient who develops a seizure during treatment.
History - Cerebrovascular Disease
Moderate:
enzalutamide
Enzalutamide has a moderate potential interaction with History - Cerebrovascular Disease.
Seizures occurred in 0.5% of patients receiving enzalutamide in clinical trials. Patients with predisposing factors for seizures were generally excluded. Caution is advised if using in patients with possible predisposing factors such as history of seizures, history of trauma or head injury, cerebrovascular accident or transient ischemic attack, Alzheimer's disease, meningioma or brain tumor or infection, and any unexplained loss of consciousness in the past 12 months. Enzalutamide should be discontinued permanently in any patient who develops a seizure during treatment.
Liver Disease
Moderate:
nerandomilast
Nerandomilast has a moderate potential interaction with Liver Disease.
Nerandomilast has not been investigated in patients with severe (Child-Pugh Class C) hepatic impairment and is not recommended on these patients.
Renal Dysfunction
Moderate:
enzalutamide
Enzalutamide has a moderate potential interaction with Renal Dysfunction.
Enzalutamide has not been assessed in patients with severe renal impairment or end-stage renal disease. Caution is advised if used on these patients. No initial dosage adjustment is required on patients with mild to moderate renal impairment.
Moderate:
nerandomilast
Nerandomilast has a moderate potential interaction with Renal Dysfunction.
Nerandomilast has not been studied in patients with end stage renal disease (eGFR less than 15 mL/min) and is not recommended on these patients.
Seizures
Moderate:
enzalutamide
Enzalutamide has a moderate potential interaction with Seizures.
Seizures occurred in 0.5% of patients receiving enzalutamide in clinical trials. Patients with predisposing factors for seizures were generally excluded. Caution is advised if using in patients with possible predisposing factors such as history of seizures, history of trauma or head injury, cerebrovascular accident or transient ischemic attack, Alzheimer's disease, meningioma or brain tumor or infection, and any unexplained loss of consciousness in the past 12 months. Enzalutamide should be discontinued permanently in any patient who develops a seizure during treatment.
Report options
More resources
enzalutamide
A total of 703 drugs are known to interact with enzalutamide.
- Enzalutamide is in the following drug classes: antiandrogens, hormones/antineoplastics.
- Enzalutamide is used to treat Prostate Cancer.
nerandomilast
A total of 59 drugs are known to interact with nerandomilast.
- Nerandomilast is in the drug class selective phosphodiesterase-4 inhibitors.
- Nerandomilast is used to treat the following conditions:
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.